## **BAUSCH**-Health

## 2016

Register for email alerts. All Categories **Archive Date** 12/12/16 **Title** Valeant Appoints William D. Humphries As EVP, Dermatology Download **PDF** 12/08/16 **Date Title** Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118 **Download PDF** 11/29/16 **Date Title** Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor® **Download PDF Date** 11/17/16 **Title** Valeant Comments On Issued Philidor Criminal Charges **Download PDF** 

11/10/16 **Date** 

**Title** 

valcanti namiaccanca	als To Participate In Healthcare Conferences
Download	PDF
Date	11/08/16
Title	
Valeant Reports Third C	Quarter 2016 Financial Results
Download	PDF
Date	11/01/16
Title	
Valeant Pharmaceutica	als Comments On Press Report Regarding Its Gastroenterology Business Unit
Download	PDF
Date	10/31/16
Title	
Valeant Pharmaceutica	als Comments On Press Report
Download	PDF
Date	10/17/16
Title	
Valeant Announces Thi	rd Quarter Financial Results Date And Conference Call Details
Download	PDF
Date	10/14/16
Title	
Valeant Patient Access	And Pricing Committee Comments On Recent Pricing Action Decisions
Download	PDF
Date	10/06/16
Title	
Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer	

Date	09/16/16
Title	
Valeant Comments On Discour	nt And Rebate Program For Nitropress And Isuprel
Download	PDF
Date	09/06/16
Title	
Valeant And Progenics Annour	ce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets
Download	PDF
Date	08/30/16
Title	
Valeant Pharmaceuticals To Pa	rticipate In September Healthcare Conferences
Download	PDF
Date	08/22/16
Title	
Valeant Pharmaceuticals Appo Financial Officer	ints Paul S. Herendeen As Executive Vice President, Finance And Chief
Download	PDF
Date	08/18/16
Title	
Valeant Pharmaceuticals Recei	ves Lender Consent For Credit Facility Amendment
Download	PDF
Date	08/10/16
Title	
Valeant Pharmaceuticals Comr	nents On SDNY Investigation
Download	PDF
Date	08/09/16

<b>Title</b> Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results	
Download	PDF
Date	08/08/16
<b>Title</b> Valeant Pharmaceuticals Ar Wilson Disease	nounces Significant Support For Education And Research Regarding
Download	PDF
Date	08/08/16
<b>Title</b> Valeant Pharmaceuticals Ar	nounces Relaunch Of Generic Ofloxacin Otic Solution
Download	PDF
Date	08/08/16
Title	
Valeant Pharmaceuticals Ar Canada	nounces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And
Download	PDF
Date	08/08/16
Title	
Valeant Pharmaceuticals Ar	nounces Changes To Executive Management Team
Download	PDF
Date	07/28/16
Title  Valeant Pharmaceuticals Ar	nounces The Addition Of Sarah B. Kavanagh To Its Board Of Directors
Download	PDF
Dit	or/or/tre
Date	07/22/16
<b>Title</b> Valeant Pharmaceuticals Re	ceives Complete Response Letter From The FDA

Download	PDF
Date	07/19/16
Title	
	Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid- in Adults with Chronic Non-cancer Pain
Download	PDF
Date	07/19/16
Title	
FDA Advisory Committ Severe Plaque Psoriasi	tee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-s
Download	PDF
Date	07/15/16
Title	
Valeant Pharmaceutica	als Announces Second Quarter Results Conference Call Date And Details
Download	PDF
Date	07/14/16
Title	
Valeant Pharmaceutica	als Comments On Recent Stock Transactions
Download	PDF
Date	07/06/16
Title	
	cox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution Results in American Journal of Ophthalmology
Download	PDF
Date	07/01/16
Title	
Valeant Pharmaceutica	als Announces New Licensing Arrangement For Brodalumab In Europe

Download	PDF
Date	06/27/16
Title	
Canadian Shopper Study N	ames Bausch + Lomb Most Trusted Brand For Contact Lens Care
Download	PDF
Date	06/17/16
Title	
Valeant Pharmaceuticals A	nnounces Significant Investments In Canadian Operations
Download	PDF
Date	06/16/16
Title	
Valeant Pharmaceuticals A	nnounces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin
Download	PDF
Date	06/15/16
Title	
Valeant Pharmaceuticals A	ppoints Thomas W. Ross, Sr. Lead Independent Director
Download	PDF
Date	06/09/16
Title	
Valeant To Participate In FD	OA Advisory Committee Meeting On July 19
Download	PDF
Date	06/07/16
Title	
Valeant Pharmaceuticals To	Webcast 2016 Annual Meeting Of Shareholders
Download	PDF
Date	06/07/16
	Page 6 of

## **Title** Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results **Download PDF** 06/03/16 **Date Title** Valeant Pharmaceuticals Receives Additional Notice Of Default Under Indentures Due To Delayed Form 10-Q Filing **Download PDF** 06/01/16 **Date Title** Valeant Pharmaceuticals To Present Six Abstracts At 2016 ASCO Annual Meeting **Download PDF** 05/31/16 **Date Title** Valeant Pharmaceuticals To Hold Conference Call On June 7, 2016 **Download PDF** 05/26/16 **Date Title** Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller **Download PDF** 05/23/16 **Date Title** Bausch + Lomb Wins Walmart "Supplier of the Year" Award **Download PDF** 05/19/16 **Date Title** Valeant Pharmaceuticals Receives Notice Of Default From Bondholders

Download	PDF
Date	05/18/16
Title	
Valeant Pharmaceuticals	To Participate At The UBS Global Healthcare Conference
Download	PDF
Date	05/16/16
Title	
Valeant Pharmaceuticals	Provides Update Regarding Regulatory Matters
Download	PDF
Date	05/16/16
Title	
Valeant Dharmaceuticals	Appaulage Expanded Discounts For Nitropress And Isuard
valeant Fhamhaceaticals	s Announces Expanded Discounts For Nitropress And Isuprel
Download	PDF
Download	PDF
Download  Date  Title	PDF
Download  Date  Title  Valeant Pharmaceuticals	PDF 05/09/16
Download  Date  Title  Valeant Pharmaceuticals Quarter Guidance	05/09/16 s Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 Fire
Download  Date  Title  Valeant Pharmaceuticals Quarter Guidance  Download	05/09/16 S Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 Fire
Download  Date  Title  Valeant Pharmaceuticals Quarter Guidance  Download  Date  Title	05/09/16 S Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 Fire
Download  Date  Title  Valeant Pharmaceuticals Quarter Guidance  Download  Date  Title  Valeant Pharmaceuticals	05/09/16 S Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 Fin  PDF  05/05/16
Download  Date  Title  Valeant Pharmaceuticals Quarter Guidance  Download  Date  Title  Valeant Pharmaceuticals Drugs	O5/09/16  S Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 Fin  PDF  O5/05/16  S Announces Patient Access And Pricing Committee To Oversee Pri
Download  Date  Title  Valeant Pharmaceuticals Quarter Guidance  Download  Date  Title  Valeant Pharmaceuticals Drugs  Download	O5/09/16  S Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 Fin  PDF  O5/05/16  S Announces Patient Access And Pricing Committee To Oversee Pricing C
Download  Date  Title  Valeant Pharmaceuticals Quarter Guidance  Download  Date  Title  Valeant Pharmaceuticals Drugs  Download  Date  Title  Title  Title  Title  Title  Title  Title  Title	O5/09/16  S Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 Fin  PDF  O5/05/16  S Announces Patient Access And Pricing Committee To Oversee Pricing C

Date	05/03/16
Title	
Joseph C. Papa Assumes	Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals
Download	PDF
Date	04/29/16
Title	
Valeant Announces Nomi	nees For Election To Board Of Directors
Download	PDF
Date	04/29/16
Title	
Valeant Pharmaceuticals	Files Annual Report On Form 10-K For Year Ended December 31, 2015
Download	PDF
Date	04/25/16
Title	
Valeant Names Joseph C. Pharmaceuticals	Papa To Be Chairman And Chief Executive Officer Of Valeant
Download	PDF
Date	04/22/16
Title	
Valeant Pharmaceuticals K Filing	Receives Additional Notices Of Default Under Indentures Due To Delayed 10-
Download	PDF
Date	04/13/16
Title	
Valeant Pharmaceuticals	Provides Update Regarding Regulatory Matters
Download	PDF
Date	04/12/16

<b>Title</b> Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Due To Delayed 10-K Filing	
Download	PDF
Date	04/11/16
<b>Title</b> Valeant Board Of Directors Committee on Aging	s Issues Statement On J. Michael Pearson's Cooperation With Senate
Download	PDF
Date	04/07/16
<b>Title</b> Valeant Pharmaceuticals F	Receives Lender Consent For Credit Facility Amendment
Download	PDF
Date	04/05/16
Title	
Valeant Ad Hoc Committee Matters	e Announces Completion Of Its Review Of Philidor And Related Accounting
Download	PDF
Date	04/04/16
Title	
Valeant and Progenics Anr	nounce PDUFA Date Extension for Oral RELISTOR
Download	PDF
Date	03/30/16
<b>Title</b> Valeant Pharmaceuticals Launches Credit Facility Amendment	
Download	PDF
Date	03/21/16

**Title** Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update Download **PDF Date** 03/15/16 **Title** /CORRECTION -- Valeant Pharmaceuticals International, Inc./ **Download PDF** 03/09/16 **Date Title** Valeant And R&O Pharmacy End Litigation Download **PDF** 03/09/16 **Date Title** Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board **Download PDF Date** 03/07/16 **Title** Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016 Download **PDF** 03/07/16 **Date Title** Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016 **Download PDF** 03/03/16 Date **Title** Valeant Pharmaceuticals Comments On Management Change

**Download PDF** 03/02/16 **Date Title** Valeant Pharmaceuticals Announces Management Change **Download PDF** 02/28/16 Date **Title** Valeant Pharmaceuticals Announces Management And Business Update **Download PDF** 02/22/16 **Date Title** Valeant Ad Hoc Committee has Made Substantial Progress in Its Review of Philidor and Related **Accounting Matters Download PDF** Date 01/25/16 **Title** Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis **Download PDF** 01/25/16 **Date Title** Valeant Provides Update On J. Michael Pearson **Download PDF Date** 01/06/16 **Title** Valeant Names Howard B. Schiller Interim CEO Download **PDF** 

**Date** 01/04/16

**Title** 

Valeant Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference

**Download** 

PDF





**Investor Inquiries** 

<u>ir@bauschhealth.com</u> 877-281-6642 514-856-3855 (Canada) LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS

EMAIL PAGE

**RSS FEED** 

Media inquiries

<u>Corporate.communications@bauschhealth.com</u> 908-569-3692

Use of this site signifies your agreement to the Legal Notice and Privacy Policy. ©2025 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: <u>DO NOT SELL MY</u>

<u>PERSONAL INFORMATION</u>

